2d2u on the week and making it to the target will trigger the 50% rule on the month. This may be a nice swing if it can hold and keep pushing.
The PEAD projected a Bullish outlook for $AMGN after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
Amgen Inc. has been trending up since December last year. We can observe that price has recently reached a higher high at the resistance level of 258.00. Therefore, we are only looking for buy entries for this stock. 258.00 is a very strong resistance level; we can see from the past that prices have rejected more than 9 times from this level. After rejections,...
Desicion to Buy. Entry Price = $254.00. Target Price=$258.00. Stop Price=$250.00.
Sellers have been present in Amgen , keeping this stock under the 240 zone since FEB's pop. Lot of dark pool and call option flow showing bullish signs as the stock continues consolidating and eating away supply. I think the bulls win here, alarm it for $240 as a good long idea. I'm in a starter JAN 275c looking to add more positions upon breakout...
Desicion to Buy. Entry Price = $236.50. Target Price=$240.25. Stop Price=$232.75
Desicion to Buy. Entry Price = $235.86. Target Price=$240.50. Stop Price=$231.22
$AMGN is one of my favorite bio tech stocks as it has solidified its place as a winner over the years. They had a bit of a slowdown and consolidation over the past few years as they didn't have as much involvement with COVID, but certainly didn't lose too much value. Watch for a 4hr close above $241.50 to send us back to $260+ over next few weeks.
The PEAD projected a Bullish outlook for $AMGN after a Positive Under reaction following its earnings release placing the stock in drift A with an expected accuracy of 100%.
on this entry we have a distribution phase now we see a support point which confirmed the testing of the climactic movement
As a rule, when I see a crooked W, I steer clear and watch it if it is a security I want. The impulse/long leg/is to the downside whereas a bullish crooked M pattern, the impulse leg is up. We are all different. Crooked Ws are not always bearish, but it just gets too complicated for this post so I will stop there. For the most part, a W is bearish. I have...
Possible stop under C. No recommendation. Short percent is 2.14%. Earnings due again on 5-18 BMO. W not so attractive but have noted that securities often pull to the middle hump of the W and this one is very close. With double bottoms often there is a W associated with the double bottom. Ws can be bearish. The tail of a red long legged doji candle did hit...
Top pharma pick right now other than BMY. P/E 13.11 with forecasted 6-7% earnings growth and an EPS yield of 7.62%. Historic Norm P/E 18.89 ^ 10 Y = 14.50 ^ 5 Y = 14.25 3.49% Div payer. Valuation estimate based on 2023 forecasted EPS (19.11) and P/E of 14.25 = $272.32
Immediate targets 211, 200,186. Invalidation at 279. We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely...
Commodity Channel Index (CCI) Jan 26 Daily Short-Term Bearish Volume 2,799,706 Close Price 222.54 Pattern Duration 1 day Triple Moving Average Crossover (4-day 9-day 18-day) Jan 27 Daily Short-Term Bearish Volume 2,492,054 Close Price 224.00 Pattern Duration 1 day Commodity Channel Index (CCI) Jan 27 Daily Other Volume 2,492,054 Close Price 224.00 Pattern Duration 1 day
AMGN looks ready to rip. Bullish crossover on the Stochastic, Super Trend is green and price closed above the 200 EMA. Looking for $230+ this week.
Located close to dynamic resistance. Be careful on the BUY side. The RSI has also reached the buy saturation zone. BUY after breaking the dynamic resistance and stabilizing it high.
Amgen Inc. discovers, develops, manufactures and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. It has agreements with Novartis, Bayer, among others. Revenue TTM 25.7B Net Income TTM 5.6B EBITDA TTM 12.1B EBITDA margin TTM 47.1%. Debt/EBITDA TTM 3.05x